A study that continues from APD334-003 which investigates the safety and effectiveness of treatment with the drug APD334 in patients with ulcerative colitis (a form of inflammatory bowel disease)
- Conditions
- lcerative colitisTherapeutic area: Diseases [C] - Digestive System Diseases [C06]MedDRA version: 20.1Level: LLTClassification code 10045365Term: Ulcerative colitisSystem Organ Class: 100000004856
- Registration Number
- EUCTR2015-002109-12-AT
- Lead Sponsor
- Arena Pharmaceuticals, Inc.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 156
1. Evidence of a personally signed and dated informed consent document
2. Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures and is deemed an appropriate candidate for participation in this long-term extension study
3. Eligible female patients must be:
a. non-pregnant, evidenced by a negative urine dipstick pregnancy test at Week 12 of study APD334-003
b. non-lactating
c. sexually abstinent, surgically sterile, postmenopausal, or agree to continue to use an accepted method of birth control during and for at least 30 days after last study medication administration. Acceptable methods of birth control are:
- hormonal contraceptives (patients should be consistently taking the hormonal contraceptive for at least 3 months [90 days] prior to screening);
- double barrier method (condom or occlusive cap [diaphragm or cervical cap] with spermicide);
- an intrauterine device;
- surgical sterility for at least 6 months prior to screening for tubal ligation performed laparoscopically, hysterectomy and/or bilateral oophorectomy; and/or postmenopausal (defined as at least 2 years without menses).
Contraceptive measures such as Plan B (used after unprotected sex) are not acceptable methods of contraception for this study.
4. Eligible male patients will either be:
- Surgically sterile (i.e., vasectomy), for at least 3 months (90 days) prior to screening or
- Agree to use a condom with spermicide when sexually active with a female partner who is not using an acceptable method of birth control during the study and for 30 days after last study medication administration
5. Eligible male and female patients must agree not to participate in a conception process (i.e. active attempt to become pregnant or to impregnate, sperm donation, in vitro fertilization) for 30 days after the last dose of study drug
6. Completion of the APD334-003 study.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 148
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 9
1. Patients who were withdrawn from study drug treatment due to any AE or SAE, or patients who did not complete the APD334-003 study
2. Female patients who wish to become pregnant
3. Other severe acute or chronic medical or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for entry into this study
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method